Profile
| Metric | Value |
|---|---|
| Full Name | NovoCure Limited |
| Ticker | NASDAQ: NVCR |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Country | Switzerland |
| IPO | |
| Indexes | Not included |
| Website | novocure.com |
| Employees | 1,488 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $13.12 | |
| Price, 1D Change | +1.47% | |
| Market Cap | $1B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.24 | |
| Revenue | $605M | |
| Revenue, 1Y Change | +18.82% | |
| EPS | -$1.56 | |
| EPS, 1Y Change | +19.64% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$1.56 | |
| EPS Estimate | -$1.38 | |
| EPS Est. Change | +11.57% | |
| Revenue | $605.22M | |
| Revenue Estimate | $651.21M | |
| Revenue Est. Change | +7.60% | |
| Current Price | $13.12 | |
| Price Target | - | $24.00 |
| Price Tgt. Change | - | +82.93% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$2.02 | -$1.95 | +3.66% | |
| -$1.30 | -$1.56 | -20.63% | |
| -$1.38 | N/A | +11.57% | |
| -$1.48 | N/A | +5.17% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $506.89M | $509.34M | +0.48% | |
| $605.24M | $605.22M | -0.00% | |
| $651.21M | N/A | +7.60% | |
| $687.78M | N/A | +13.64% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | -56.25% | |
| Price, 3Y | -82.11% | |
| Market Cap, 1Y | -54.86% | |
| Market Cap, 3Y | -80.93% | |
| Revenue, 1Y | +18.82% | |
| Revenue, 3Y | +13.12% | |
| EPS, 1Y | +19.64% | |
| EPS, 3Y | -177.22% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $13.12 | |
| SMA 200 | $14.70 | |
| SMA 200 vs Price | +12.07% | |
| SMA 50 | $12.48 | |
| SMA 50 vs Price | -4.85% | |
| Beta | 1.24 | |
| ATR | $0.53 | |
| 14-Day RSI | 53.87 | |
| 10-Day Volatility | 33.04% | |
| 1-Year Volatility | 57.43% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $605.22M | |
| EPS | -$1.56 | |
| Gross Profit | $468.04M | |
| Gross Margin | 77.33% | |
| Operating Profit | -$170.50M | |
| Operating Margin | -28.17% | |
| Net Income | -$168.63M | |
| Net Margin | -27.86% | |
| EBITDA | -$109.58M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 1.82 | |
| Current Ratio | 1.46 | |
| Quick Ratio | 1.42 | |
| Interest Coverage | -11.68 | |
| F-Score | 3 | |
| Altman Z-Score | 0.20 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 2.29 | |
| PB Ratio | 4.30 | |
| EV/EBITDA | -7.59 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $360.18M | |
| Cash & Equivalents | $163.77M | |
| Total Assets | $1.24B | |
| Current Assets | $1.11B | |
| Total Liabilities | $880.61M | |
| Current Liabilities | $756.38M | |
| Total Debt | $683.34M | |
| Short Term Debt | $566.07M | |
| Accounts Payable | $105.09M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $775.72M | |
| Operating Expenses | $638.54M | |
| Cost Of Goods Sold | $137.18M | |
| SG&A | $428.89M | |
| D&A | $11.24M | |
| Interest Expense | $10.34M | |
| Income Tax | $37.47M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$26.37M | |
| CFI | -$140.24M | |
| CFF | $90.32M | |
| Capex | $42.86M | |
| Free Cash Flow | -$69.22M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| HC Wainwright & Co. | → | |
| JP Morgan | → | |
| Wells Fargo | → | |
| Ladenburg Thalmann | ||
| Piper Sandler | → | |
| Piper Sandler | → | |
| Wedbush | → | |
| JP Morgan | → | |
| HC Wainwright & Co. | → | |
| Piper Sandler | → |
Analyst sentiment
Institutional ownership
Screeners with NVCR
Data Sources & References
- NVCR Official Website www.novocure.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1645113/000164511325000042/0001645113-25-000042-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1645113/000164511325000002/0001645113-25-000002-index.htm
- NVCR Profile on Yahoo Finance finance.yahoo.com/quote/NVCR
- NVCR Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/nvcr
FAQ
What is the ticker symbol for NovoCure Limited?
The ticker symbol for NovoCure Limited is NASDAQ:NVCR
Does NovoCure Limited pay dividends?
No, NovoCure Limited does not pay dividends
What sector is NovoCure Limited in?
NovoCure Limited is in the Healthcare sector
What industry is NovoCure Limited in?
NovoCure Limited is in the Medical Devices industry
What country is NovoCure Limited based in?
NovoCure Limited is headquartered in Switzerland
When did NovoCure Limited go public?
NovoCure Limited initial public offering (IPO) was on October 1, 2015
Is NovoCure Limited in the S&P 500?
No, NovoCure Limited is not included in the S&P 500 index
Is NovoCure Limited in the NASDAQ 100?
No, NovoCure Limited is not included in the NASDAQ 100 index
Is NovoCure Limited in the Dow Jones?
No, NovoCure Limited is not included in the Dow Jones index
When was NovoCure Limited last earnings report?
NovoCure Limited's most recent earnings report was on October 30, 2025
When does NovoCure Limited report earnings?
The next expected earnings date for NovoCure Limited is February 26, 2026